Donna Albertson

Prof. Donna Albertson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BSBrian Schmidt
Brian Schmidt
JKJustin Kuczynski
Justin Kuczynski
ABAditi Bhattacharya
Aditi Bhattacharya
BHBing Huey
Bing Huey
PCPatricia M. Corby
Patricia M. Corby
Muy-Teck TehMuy-Teck Teh
Muy-Teck Teh
Individual bacteria and shifts in the composition of the microbiome have been associated with human diseases including cancer. To investigate changes in the microbiome associated with oral cancers, we profiled cancers and anatomically matched contralateral normal tissue from the same patient by sequencing 16S rDNA hypervariable region amplicons. In cancer samples from both a discovery and a subsequent confirmation cohort, abundance of Firmicutes (especially Streptococcus) and Actinobacteria (especially Rothia) was significantly decreased relative to contralateral normal samples from the same patient. Significant decreases in abundance of these phyla were observed for pre-cancers, but not when comparing samples from contralateral sites (tongue and floor of mouth) from healthy individuals. Weighted UniFrac principal coordinates analysis based on 12 taxa separated most cancers from other samples with greatest separation of node positive cases. These studies begin to develop a framework for exploiting the oral microbiome for monitoring oral cancer development, progression and recurrence.

7 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAditi Bhattacharya
Aditi Bhattacharya
MJMalvin N. Janal
Malvin N. Janal
RVRatna Veeramachaneni
Ratna Veeramachaneni
IDIgor Dolgalev
Igor Dolgalev
ZDZinaida Dubeykovskaya
Zinaida Dubeykovskaya
DADonna Albertson
Donna Albertson
Oral cancer patients experience pain at the site of the primary cancer. Patients with metastatic oral cancers report greater pain. Lack of pain identifies patients at low risk of metastasis with sensitivity = 0.94 and negative predictive value = 0.89. In the same cohort, sensitivity and negative predictive value of depth of invasion, currently the best predictor, were 0.95 and 0.92, respectively. Cancer pain is attributed to cancer-derived mediators that sensitize neurons and is associated with increased neuronal density. We hypothesized that pain mediators would be overexpressed in metastatic cancers from patients reporting high pain. We identified 40 genes overexpressed in metastatic cancers from patients reporting high pain (n = 5) compared to N0 cancers (n = 10) and normal tissue (n = 5). The genes are enriched for functions in extracellular matrix organization and angiogenesis. They have oncogenic and neuronal functions and are reported in exosomes. Hierarchical clustering according to expression of neurotrophic and axon guidance genes also separated cancers according to pain and nodal status. Depletion of exosomes from cancer cell line supernatant reduced nociceptive behavior in a paw withdrawal assay, supporting a role for exosomes in cancer pain. The identified genes and exosomes are potential therapeutic targets for stopping cancer and attenuating pain.

21 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
Tu Huu NguyenTu Huu Nguyen
Tu Huu Nguyen
KIKenji Inoue
Kenji Inoue
PLParker Lewis
Parker Lewis
AKAmmar Khan
Ammar Khan
JHJun Hyeong Hwang
Jun Hyeong Hwang
BSBrian Schmidt
Brian Schmidt
Oral cancer patients suffer pain at the site of the cancer. Calcitonin gene related polypeptide (CGRP), a neuropeptide expressed by a subset of primary afferent neurons, promotes oral cancer growth. CGRP also mediates trigeminal pain (migraine) and neurogenic inflammation. The contribution of CGRP to oral cancer pain is investigated in the present study. The findings demonstrate that CGRP-immunoreactive (-ir) neurons and neurites innervate orthotopic oral cancer xenograft tumors in mice. Cancer increases anterograde transport of CGRP in axons innervating the tumor, supporting neurogenic secretion as the source of CGRP in the oral cancer microenvironment. CGRP antagonism reverses oral cancer nociception in preclinical oral cancer pain models. Single-cell RNA-sequencing is used to identify cell types in the cancer microenvironment expressing the CGRP receptor components, receptor activity modifying protein 1 Ramp1 and calcitonin receptor like receptor (CLR, encoded by Calcrl). Ramp1 and Calcrl transcripts are detected in cells expressing marker genes for Schwann cells, endothelial cells, fibroblasts and immune cells. Ramp1 and Calcrl transcripts are more frequently detected in cells expressing fibroblast and immune cell markers. This work identifies CGRP as mediator of oral cancer pain and suggests the antagonism of CGRP to alleviate oral cancer pain.

21 May 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KUKenichiro Uchida
Kenichiro Uchida
RVRatna Veeramachaneni
Ratna Veeramachaneni
BHBing Huey
Bing Huey
ABAditi Bhattacharya
Aditi Bhattacharya
BSBrian Schmidt
Brian Schmidt
DADonna Albertson
Donna Albertson
Metastasis to the cervical (neck) lymph nodes is one of the most significant clinical factors responsible for death from oral squamous cell carcinoma (SCC). Therefore, the lymph nodes are frequently removed when the tumor is excised (neck dissection), even though the majority of patients will not benefit from the extra surgery. Two subtypes of oral SCC distinguished by the presence of tumor genomic aberrations +3q, -8p, +8q and/or +20 differ in risk for metastasis – high for the 3q8pq20 subtype, harboring one or more of the aberrations and low for the non-3q8pq20 subtype, lacking these alterations. A prior analysis of the literature suggested genes differentially methylated in the two subtypes. Therefore, the goal of this study was to further investigate the methylation status of candidate biomarkers of the non-3q8pq20 subtype, and evaluate their utility for identifying patients at low risk for metastasis.


8 July 2022 in Advanced Biology
Verified
Journal Article
Open access
ZDZinaida A. Dubeykovskaya
Zinaida A. Dubeykovskaya
Tu Huu NguyenTu Huu Nguyen
Tu Huu Nguyen
Paulina Daniela Ramirez GarciaPaulina Daniela Ramirez Garcia
Paulina Daniela Ramirez Garcia
BSBrian L. Schmidt
Brian L. Schmidt
DADonna Albertson
Donna Albertson
Oral cancer pain is attributed to the release from cancers of mediators that sensitize and activate sensory neurons. Intraplantar injection of conditioned media (CM) from human tongue cancer cell line HSC‐3 or OSC‐20 evokes nociceptive behavior. By contrast, CM from noncancer cell lines, DOK, and HaCaT are non‐nociceptive. Pain mediators are carried by extracellular vesicles (EVs) released from cancer cells. Depletion of EVs from cancer cell line CM reverses mechanical allodynia and thermal hyperalgesia. CM from non‐nociceptive cell lines become nociceptive when reconstituted with HSC‐3 EVs. Two miRNAs (hsa‐miR‐21‐5p and hsa‐miR‐221‐3p) are identified that are present in increased abundance in EVs from HSC‐3 and OSC‐20 CM compared to HaCaT CM. The miRNA target genes suggest potential involvement in oral cancer pain of the toll like receptor 7 (TLR7) and 8 (TLR8) pathways, as well as signaling through interleukin 6 cytokine family signal transducer receptor (gp130, encoded by IL6ST) and colony stimulating factor receptor (G‐CSFR, encoded by CSF3R), Janus kinase and signal transducer and activator of transcription 3 (JAK/STAT3). These studies confirm the recent discovery of the role of cancer EVs in pain and add to the repertoire of algesic and analgesic cancer pain mediators and pathways that contribute to oral cancer pain.